ARTICLE | Company News

Advanced Life, Abbott, Pfizer infectious news

November 15, 2010 8:00 AM UTC

Advanced Life said it submitted a proposal to NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop an IV formulation of Restanza cethromycin. The proposal requests $38 million over five years for: preclinical testing of the ketolide antibiotic; four Phase I trials to treat anthrax, plague, tularemia and community acquired bacterial pneumonia (CABP); and one Phase II clinical trial in CABP. ...